New Toothpaste Stops Periodontal Pathogens

Researchers at the Fraunhofer Institute have identified a substance that selectively targets bacteria responsible for periodontitis, a common gum disease. This approach aims to inhibit harmful microbes without disrupting the natural balance of the oral microbiome. The technology has been further developed and commercialized into a range of oral care products by the spin-off company PerioTrap Pharmaceuticals GmbH.

Periodontitis is a widespread condition that can lead to serious health consequences beyond oral health. It can progress from gingivitis, causing receding gums and tooth loss. Furthermore, the bacteria involved can enter the bloodstream, potentially contributing to systemic conditions such as diabetes, cardiovascular disease, and even Alzheimer's disease.

Conventional oral care products, like antiseptic mouthwashes containing chlorhexidine, often eliminate beneficial bacteria along with the harmful ones. This can lead to a dysbiosis, where pathogenic bacteria quickly regain dominance and the disease recurs. The newly identified compound, guanidinoethylbenzylamino imidazopyridine acetate, functions differently by inhibiting the growth of pathogens rather than outright killing them.

"Rather than simply killing gingivitis pathogens, it inhibits their growth," explained Stephan Schilling, Head of Molecular Drug Biochemistry and Therapy Development at Fraunhofer IZI. "This allows beneficial bacteria to occupy niches and helps to gently rebuild and stabilize the microbial balance in the mouth." PerioTrap developed the toothpaste in collaboration with Fraunhofer IZI and Fraunhofer IMWS, incorporating standard ingredients like abrasives and fluoride for cavity prevention alongside the novel active substance.